Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Evans-Brown

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Addiction (Abingdon, England)|August 23, 2016
New psychoactive substances: driving greater complexity into the drug problemMichael Evans-Brown, Roumen Sedefov
Handbook of Experimental Pharmacology|September 9, 2018
Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control MeasuresMichael Evans-Brown, Roumen Sedefov
Drug Testing and Analysis|April 1, 2010
Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit marketMichael Evans-Brown, Andreas Kimergård, Jim McVeigh
Addiction (Abingdon, England)|July 20, 2013
Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information agePaul Griffiths, Michael Evans-Brown, Roumen Sedefov
Drug Testing and Analysis|June 22, 2017
Assessing the toxicological significance of new psychoactive substances in fatalitiesSimon Elliott, Roumen Sedefov, Michael Evans-Brown
Addiction (Abingdon, England)|January 16, 2014
The (mis)use of psychoactive medicines: getting the balance right in complex systemsPaul Griffiths, Michael Evans-Brown, Roumen Sedefov
Lancet (London, England)|November 6, 2008
The dire consequences of doping?Michael Evans-Brown, Rob Dawson, Jim McVeigh
BMJ (Clinical Research Ed.)|February 25, 2011
Should "legal highs" be regulated as medicinal products?Michael Evans-Brown, Mark A Bellis, Jim McVeigh
Adicciones|August 8, 2012
Human enhancement drugs and the pursuit of perfectionJim McVeigh, Michael Evans-Brown, Mark A Bellis
Addiction (Abingdon, England)|January 20, 2019
Fentanils: a serious threat to public healthJane Mounteney, Paul Griffiths, Roumen Sedefov, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Addiction (Abingdon, England)|August 23, 2016
New psychoactive substances: driving greater complexity into the drug problemMichael Evans-Brown, Roumen Sedefov
Handbook of Experimental Pharmacology|September 9, 2018
Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control MeasuresMichael Evans-Brown, Roumen Sedefov
Drug Testing and Analysis|April 1, 2010
Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit marketMichael Evans-Brown, Andreas Kimergård, Jim McVeigh
Addiction (Abingdon, England)|July 20, 2013
Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information agePaul Griffiths, Michael Evans-Brown, Roumen Sedefov
Drug Testing and Analysis|June 22, 2017
Assessing the toxicological significance of new psychoactive substances in fatalitiesSimon Elliott, Roumen Sedefov, Michael Evans-Brown
Addiction (Abingdon, England)|January 16, 2014
The (mis)use of psychoactive medicines: getting the balance right in complex systemsPaul Griffiths, Michael Evans-Brown, Roumen Sedefov
Lancet (London, England)|November 6, 2008
The dire consequences of doping?Michael Evans-Brown, Rob Dawson, Jim McVeigh
BMJ (Clinical Research Ed.)|February 25, 2011
Should "legal highs" be regulated as medicinal products?Michael Evans-Brown, Mark A Bellis, Jim McVeigh
Adicciones|August 8, 2012
Human enhancement drugs and the pursuit of perfectionJim McVeigh, Michael Evans-Brown, Mark A Bellis
Addiction (Abingdon, England)|January 20, 2019
Fentanils: a serious threat to public healthJane Mounteney, Paul Griffiths, Roumen Sedefov, et al.
Pageof 2